Journal
JOURNAL OF BIOCHEMISTRY
Volume 152, Issue 5, Pages 397-406Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jb/mvs104
Keywords
diacylglycerol kinase; phosphatidic acid; cancer; diabetes; epilepsy
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Japan Science and Technology Agency
- Naito Foundation
- Hamaguchi Foundation for the Advancement of Biochemistry
- Daiichi-Sankyo Foundation of Life Science
- Terumo Life Science Foundation
- Futaba Electronic Memorial Foundation
- Daiwa Securities Health Foundation
- Ono Medical Research Foundation
- Japan Foundation for Applied Enzymology
- Food Science Institute Foundation
- Grants-in-Aid for Scientific Research [22370047] Funding Source: KAKEN
Ask authors/readers for more resources
Diacylglycerol kinase (DGK) phosphorylates diacylglycerol (DAG) to produce phosphatidic acid (PA) and plays an important role in signal transduction by modulating the balance between these signalling lipids. To date, 10 mammalian DGK isozymes have been identified, and these isozymes are subdivided into five groups according to their structural features. The type II DGKs, consisting of delta 1, delta 2, eta 1, eta 2 and kappa isoforms, possess a pleckstrin homology (PH) domain at their N-termini in addition to the separate catalytic region. Moreover, DGKs delta 1, delta 2 and eta 2 have a sterile alpha motif domain at their C-termini. Recent studies have revealed that type II DGKs play pivotal roles in a wide variety of mammalian signal transduction pathways for cell proliferation and differentiation and glucose metabolism and that the DGKs are involved in cancer, type II diabetes, seizures, hypospadias and bipolar disorder. This review summarizes the current knowledge on the properties and physiological functions of type II DGKs and their involvement in disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available